Winning
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, because if the product is legit, none of those games work. Unless the company is just starting out, then they will try and make it that they can't raise capital. But CYDY already has their main drug submitted to the FDA and when they submit the 2 data sets, it will be up for review. Data for Covid is already in the bag. And the bag continues to be filled. No matter what any company does to CYDY, the data will still be there.
The time to destroy Cytodyne was years and years ago when they acquired Leronlimab from Progeics and proceeded to show victory after victory after victory and were in a constant struggle for funding.
Buyouts happen all the time. Why weren't those companies destroyed by big Pharma rather then being bought out? Because the data was there.
There is no bigger buyout candidate on the market right now then CYDY. The point of no return for big Pharma to discredit them or destroy them has long passed.
BP doesn't get terrified of anybody. If they see a smaller company with a product that will threaten their market share, they simply move in and purchase the company.
For those CYDY Covid-19 clinical trials for Leronlimab, the NTC Numbers are
NCT04343651. Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
NCT04347239. Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19).
CYDY Covid-19 Trials
Coverage will come on interim results. Or an EUA permission from the FDA. They have the data now. Just have to sift through it. Also, once the BLA for the HIV indication is accepted by the FDA, that could spark some coverage. We shall see.
2 clinical trials for Covid in full effect. Nice, shiny partnership deal for manufacturing in place. Cashless options exercised to support company financially. BLA submitted for Leronlimab HIV indication. So many positives here.
So good ton see clinical trials for Covid initiated. Add to that partnership deal just announced.
Partnership
Covid Clinical Trial 1
Covid Clinical Trial 2
Good to see those two beautiful CYDY Covid-19 clinical studies registered.
CYDY Clinal Covid-19 Trial 1
CYDY Clinical Covid-19 Trial 2
ANATOMY OF CYTODYN’S CEO FINANCING – SELFLESS ACT TO SAVE COUNTLESS LIVES
Good analysis
CYDY CEO Fiancing
In addition to the 2 trials currently underway for Covid-19, they should will be receiving their letter from the FDA regarding the acceptance of their rolling BLA submission for Leronlimab for HIV use.
Add to that, EUA should given shortly.
CYDY P2 Clinical Trial for Covid
CYDY P2/3 Clinical Trial for Covid
CYDY clinical trials for Covid-19 moving right along with enrollment. Next up? Emergency =use permission from FDA.
CYDY P2 Clinical Trial for Covid
CYDY P2/3 Clinical Trial for Covid
I got .29's and sold at .65. My current batch is in at 1.01
Cytodyne's phase 2 study page for Covid. Because don't all fake companies have these set up with the FDA? Lolololol. Buy the dips. Hit pieces by STAT are meant to cause bear raids by their followers. Their articles are released after the main people are already short. They work to get the price down and then cover, buy back in, then burn all the short sellers that remain, boosting the price back up. This is what STAT does. How far they will take is is anybody's guess. Watch the charts, wait for the covering and then accumulate at the discounted prices.
Clinical trial P2
Clinical Trial P2/3
Its rather comical.
Thats just about every small cap bio in clinical stage. lol.
You're reciting a safe harbor statement for a bio in clinical stage development. Too funny.
Interesting. Thanks!
Close enough. Lol
So, the interim results come out Friday. They might even come out Thursday. The news earlier today said the results would be discussed on that stock show Friday afternoon. Which means the results will be PR's / announced beforehand..
Just so people know, CYDY's Vyrologix is not a cure for Covid-19. Its a therapeutic. Big difference.
Its a therapeutic that STOPS YOU FROM DYING from Covid-19. And its closer to approval that any other therapeutic or actual vaccine for that matter.
This should and can be the go to drug until a vaccine is actually approved by the FDA.
Know what you own. This is gold.
Versus Systems Completes Share Exchange with Animoca Brands under Mutual Investment Agreement
Mutual Investment to Drive In-Game Rewards Development in China, US Markets[/I]
Vancouver, British Columbia, April 20, 2020 - Versus Systems Inc. ("Versus" or the “Company”) (CSE: VS) (OTCQB: VRSSF) (FRANKFURT: BMVA) is pleased to announce that it has completed a mutual investment agreement with Animoca Brands Corporation Limited (ASX: AB1, “Animoca Brands) (the “Agreement”) which was previously announced on August 15, 2019. The goal of the Agreement is to create greater alignment between the two companies as they work to bring rewards to the millions of active players playing Animoca games – and to grow both programs further into the $35.5B1 annual US gaming market and the $36.5B1 annual Chinese gaming market.
Pursuant to the Agreement, Animoca Brands will issue 4,327,431 AB1 shares to Versus and Versus will issue 3,036,739 Versus shares to Animoca Brands, each issuance being equal in value to USD $500,000. Pricing of the Versus shares issued to Animoca Brands is based on the higher of CAD $0.23 and the 21-day volume weighted average price (VWAP) of Versus shares on the approval date. Pricing of the Animoca Brands shares issued to Versus is based on the higher of AU $0.18 and the 21-day volume weighted average price of AB1 shares on the approval date......
Versus Systems Completes Share Exchange with Animoca
Versus Systems Executive Chairman Keyvan Peymani to Lead Asian Expansion
Peymani to Launch Versus Prizing Platform in $150B Gaming and Advertising Markets in China
Los Angeles, CA - April 17, 2020 -- Versus Systems, Inc. (“Versus”) (CSE:VS) (OTCQB:VRSSF) (FSE:BMVA) is proud to announce that newly re-appointed Executive Chairman Keyvan Peymani will be adding new areas of responsibility for Versus: leading international expansion and new global alliances. Peymani will bring Versus proprietary rewards platform into existing relationships with Animoca Brands and IClick (NASDAQ: ICLK), while also developing new strategic partnerships within the $36 Billion Chinese gaming market and the $121 Billion Chinese advertising market. Mr. Peymani brings a history of success at Netflix, Disney, Warner Bros., and Amazon and he will drive Versus efforts internationally as they bring together global game developers, publishers, marketing agencies, and brands on Versus patented rewards platform.
A senior executive who has led teams across 60 countries and forged alliances with governments, global brands and Fortune 100 companies, Mr. Peymani has secured and deepened relationships with key partners in greater China for Versus, with the goal of capitalizing on the $150 Billion dollar combined gaming and advertising markets there. Amongst recent successes are the recently announced partnerships with iClick who can reach 98% of all internet users across greater China with its dataset of over 800M Chinese consumers, and the deepening of the alliance with Animoca Brands, an industry-leading global games developer and publisher with hundreds of millions of downloads and millions of active users across their portfolio.
Said Mr. Peymani, “I am proud to expand my commitment in building Versus Systems during this unprecedented time. As online gaming and streaming surge around the world, new consumer behaviors are being created and will change the landscape for how brands reach their audiences irrevocably. Performance marketing tools will be critical for any advertisers wishing to remain relevant, and Versus Systems market-leading toolset and approach are the right solution presented at the right time. I could not be more excited for our growth and prospects as we continue to add brands and partners around the world.......
Keyvan Peymani to Lead Asian Expansion
Looking to add some more. To be honest, with such low liquidity, I know the money will be safe. Plus there is a small surge in volume with a 100K block that went through. Maybe something is up? Normally, when there are big blocks going through, something is on the horizon.
Won't do too much though. Just round up my current numbers. Make my holdings look a little prettier. Fingers crossed.
Versus Partners with Kast to Expand Beyond Gaming Into Streaming Video
Versus to bring rewards to the $250 Billion global video streaming market
Los Angeles, California, April 14, 2020 - Versus Systems, Inc. ("Versus") (CSE:VS) (OTCQB:VRSSF) (FRANKFURT:BMVA) today announces an agreement with Kast to
bring Versus’ proprietary in-app rewards technology to Kast’s successful watch party platform.
This is an important step for Versus in that Kast is the first non-gaming content partner to integrate the Versus rewards platform. Social streaming, watch parties and video are a part of what Business Wire estimates as a $250 Billion dollar global streaming market that is estimated to grow at 19% CAGR through 2024.................
Versus Partners with Kast
I know exactly the kind of articles you mean. Of course, I have only seen them for publicly traded companies because the only point for them is to boost share price. This is privately company and they have no reason to do so.
Additionally, there are no recognized statements that they were hired for writing the article. Additionally, it would say 'paid program' next the the author's name, as it does with all of Forbe's paid for articles. It does not say that here.
Whats going on is, Mojo Vision has done a mass media blitz regarding their smart lens product through twitter, and various media outlets, regarding their product that is no where near becoming a reality. All a tech writer (all of which whom saw the mojo articles), has to do is a search the top 10 companies involved in smart contact lens development to see if Mojo is a top company. They are not. Unless they are now due to their media blitz. But they will find Inwith is and has been for some time. Add to that, being that InWith tweeted about Mojo's articles on twitter and used the same hashtags, etc, etc, any tech writer now researching Mojo Vision on Twitter, is going to see what InWith was tweeting as well. And InWith and what they have, makes a for a great article. I'm not surprised at all that Charlie Fink decided to write an article about them.
Great Forbes article
InWith Corporation, which holds key enabling IP in augmented contact lenses, has been at work with Bausch and Lomb (NYSE: BHC) to develop smart contacts for the past year. InWith plans for an Institutional Review Board approval this year on first prototypes. InWith co-founder and CEO Michael Hayes says the unique marriage marriage of highly biocompatible materials with 3-D flexible microelectronics embedded into molded hydrogel devices, which InWith calls “smart biology,” may be on the market “in the near future.”
https://www.forbes.com/sites/charliefink/2020/03/09/inwith-puts-smart-tech-in-bausch-and-lomb-lenses/#7c5b42b3796a
With these types of low liquid plays, all we have going for us is luck and timing.
Found the reason for the surge.
Did some digging around regarding the latest private placement from February 13, 2020, that netted the company $600K on 1.4M shares bought at $0.25CAN
private placement
They filed a form 9 which lists who the buyers are
Form 9
1. Dr. Shafik Thobani Inc. - 200,000 shares
2. Canadian Palladium Resources Inc.- 1,000,000 shares
3. Galloway Financial Services Inc. - 1,200,000
Couldn't find anything on numbers 1 & 3 in regards to why they chose to purchase. But number 2...Well, that speaks volumes. The same people that run that company are the money people behind Versus. They are the ones who orchestrated Versus Systems going private. They ran the process of having Versus take over the ticker of a shell.
What does this mean? Nothing but good things!!!!! If the main billionaire who runs Canadian Palladium Resources Inc, and controls the majority of Versus shares, just bought $250K of VS through his other start up company, he must be thinking this gonna go big time.
Could a buyout be in the works? Could another major event be close at hand? Regardless, something is happening and smart money is accumulating. I expect big news before the end of Q1
I don't think we are at a place where we can use charts to predict anything. Liquidity is still far too low.
Once we start seeing blue chip prize providers, that's going to be the catalyst that takes us over $1.00. Not a matter of if', but 'when'. Either that or a buyout. I don't know why this hasn't been snatched up yet.
They have the patents. They have the technology. The potential market speaks for itself.
If only I had a share for every time I had a 'coulda, shoulda, woulda' moment! haha
I too wish I didn't get too greedy and bought more of the .14's instead of sitting on .13's.
All that being said, my investment here is substantial and I'll rest easy with what I do have!
Added some more the other day. I liked their recent financials up to Sept. 30 all considering. With their additional partnerships they will be in the black this current quarter. The days of sub-$0.10 are coming to an end in coming months.
I would like to say I am done acquiring, as with my latest buy the other day. That I have filled my level of risk. But, if the pps stays at these levels, or goes sub-$0.02US, as the company continues to progress, I could easily see myself acquiring additional shares. We shall see.
Seeing another surge on the Canadian side of things. My risk here is pretty much set, unless it was to fall sub $0.13US, I'm done acquiring. I'm ready for this puppy to catch wind and sail onward.
Something is cooking. Volume up big in the Canadian ticker. Broke .20CAN. Looking like the loading zone of .13-.16US is over. Damn. Almost hit my goal! Damn close though.
Slowly but surely, I am getting closer to reaching my goal for the amount of shares I want. Added another small 5K block today. Hard to believe it is staying at these levels. I firmly believe we will see fantastic revenue numbers. The valuation is insanely low for what they have. Looking to be complete with my accumulation by end of this month or next. Then will wait and see what happens and strategize my next move. Love these unicorn plays
Added some more Moovly over the last month. With the recent partnerships I have to assume that they are close to cash flow positive.
As they say, ‘get in when nobody else is.’
Also, with some crazy geopolitical events going on, I think moving some money into a company that’s standing still is way to protect against coming volatility in the general market.
Would love to hit 60K shares. After today I’m at 48K. This time next year, I believe this will be cash flow positive, in the black, and over .30.
All and all, with so many entities, be it a large blue-chip company like Samsung or Sony, or a college research lab, the era of wearable technologies is going explode onto the tech scene like no other.
As for wearables such as smart contact lenses, it seems everybody has an idea. The keys are to make so they are safe, comfortable and functional.
'Smart' Contact Lenses Might Also Monitor Eye Health
Another interesting article regarding a team of scientists in South Korea developing a smart contact lens.
https://www.usnews.com/news/health-news/articles/2019-12-10/smart-contact-lenses-might-also-monitor-eye-health
Wearables definitely have what seems seems to be a endless amount of applications. This is awesome.
Wearable Air Conditioning!
One day, soldiers could cool down on the military battlefield -- preventing heat stroke or exhaustion -- by using "wearable air conditioning," an on-skin device designed by engineers at the University of Missouri. The device includes numerous human health care applications such as the ability to monitor blood pressure, electrical activity of the heart and the level of skin hydration.
Wearable Air Conditioning
These smart glasses sound pretty amazing. 'Hong Kong Startup's Am Glass Wearable Offers Powerful Augmented Reality Smartglasses Alternative to Nreal Light'
smart glasses
Good article detailing Professor Sei Kwang Hahn and his research team including his Ph.D. student, Geon-Hui Lee, invented a smart photonic contact lens and a wearable medical device which can diagnose diabetes and treat diabetic retinopathy.
smart photonics contact lens